ZRG Partners Acquires HM Long Global Partners, Bolstering Growing Global Life Sciences Executive Search Practice
6.7.2017 14:00 | Business Wire
ZRG Partners, recognized as the fastest growing search firm in the Americas, has announced the acquisition of certain assets of HM Long Global Partners and the hiring of key leaders, expanding one of the most dynamic global Life Sciences recruiting teams in the world.
As part of the asset acquisition agreement, Helga Long, formerly the Chair and CEO of HM Long/RSVP Group, is joining ZRG Partners with a prestigious career. Helga is considered one of the world’s top executive search professionals in the Life Sciences sector, as measured by her body of work in this niche. She has helped companies globally for over 30 years with senior level talent acquisition. Prior to her merger of HM Long Global Partners and RSVP, Helga spent 10 years with another leading global search firm as a Vice Chairman of the firm’s Life Sciences Practice. Helga will remain as the CEO of HM Long Global, a division of ZRG Partners, and after the integration of the assets, will assume the role of Chief Client Officer in ZRG’s global Life Sciences practice working with the ZRG team in supporting clients around the world.
Joining Helga will be several key leaders and support team members who have been working together for over a decade including Charles Rohaut, Managing Director in France. Derick Haire will join as Senior Client Partner in Texas, as well as Lydia Coleman in Virginia.
Commenting on the acquisition, Larry Hartmann, CEO of ZRG Partners related, “Our current Life Sciences team, led by Adam El Din, as Global Practice Head and David Fortier, North American Leader, have delivered amazing results the past few years. The addition of Helga Long and the team creates the most powerful super-boutique solution for Life Sciences clients globally. We could not be more excited about the addition of the entire team that has worked together in the market for years.”
Helga Long stated, “I am thrilled to join a platform where the focus is on the client and how we can serve them best. ZRG’s sophisticated, client centric data and analytics approach in the search process will only enhance the level of work our team has already been doing in the market and create even stronger client partnerships. The alliance with ZRG creates a true 1+1 = 3 combination. I look forward to continuing to serve my clients in delivering top life science talent globally as part of this dynamic organization.”
Adam El Din commented, “I am delighted that Helga, Charles and their team are joining ZRG partners. Our team will capitalize on our expertise and network to offer our clients a partnership second to none.”
About ZRG Partners
ZRG Partners is a progressive mid-sized global executive search firm that uses a proven, data-driven approach. For over 17 years, clients have trusted ZRG Partners to recruit top talent around the world. ZRG Partners is recognized as one of the fastest growing executive search firms in the industry driven by the firm’s client focused, results driven approach grounded in integrity.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 21:33 | Tiedote
The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 15:09 | Tiedote
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 14:26 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s
Schlumberger Announces Second-Quarter 2017 Results21.7.2017 14:00 | Tiedote
Schlumberger Limited (NYSE:SLB) today reported results for the second quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2017 Mar. 31, 2017 Jun. 30, 2016
NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 10:00 | Tiedote
NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve
Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 08:00 | Tiedote
Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme